Literature DB >> 25601282

Expression of cholecystokinin2-receptor in rat and human L cells and the stimulation of glucagon-like peptide-1 secretion by gastrin treatment.

Yang Cao1, Xun Cao1, Xiao-Min Liu2.   

Abstract

Gastrin is a gastrointestinal hormone secreted by G cells. Hypergastrinemia can improve blood glucose and glycosylated hemoglobin levels. These positive effects are primarily due to the trophic effects of gastrin on β-cells. In recent years, many receptors that regulate secretion of glucagon-like peptide 1 (GLP-1) have been identified in enteroendocrine L cell lines. This led us to hypothesize that, in addition to the trophic effects of gastrin on β-cells, L cells also express cholecystokinin2-receptor (CCK2R), which may regulate GLP-1 secretion and have synergistic effects on glucose homeostasis. Our research provides a preliminary analysis of CCK2R expression and the stimulating effect of gastrin treatment on GLP-1 secretion in a human endocrine L cell line, using RT-PCR, Western blot, immunocytochemistry, and ELISA analyses. The expression of proglucagon and prohormone convertase 3, which regulate GLP-1 biosynthesis, were also analyzed by real-time PCR. Double immunofluorescence labeling was utilized to assess the intracellular localization of CCK2R and GLP-1 in L cells harvested from rat colon tissue. Our results showed that CCK2R was expressed in both the human L cell line and the rat L cells. We also showed that treatment with gastrin, a CCK2R agonist, stimulated the secretion of GLP-1, and that this effect was likely due to increased expression of proglucagon and PCSK1 (also known as prohormone convertase 3 (PC3 gene)). These results not only provide a basis for the role gastrin may play in intestinal L cells, and may also provide the basis for the development of a method of gastrin-mediated glycemic regulation.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cholecystokinin(2) receptor (CCK2R); Gastrin; Glucagon-like peptide-1 (GLP-1); NCI-H716 cell line; Rat colon

Mesh:

Substances:

Year:  2015        PMID: 25601282     DOI: 10.1016/j.acthis.2014.12.007

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  5 in total

1.  The gastrin-releasing peptide analog bombesin preserves exocrine and endocrine pancreas morphology and function during parenteral nutrition.

Authors:  Joseph F Pierre; Joshua C Neuman; Allison L Brill; Harpreet K Brar; Mary F Thompson; Mark T Cadena; Kelsey M Connors; Rebecca A Busch; Aaron F Heneghan; Candace M Cham; Elaina K Jones; Carly R Kibbe; Dawn B Davis; Guy E Groblewski; Kenneth A Kudsk; Michelle E Kimple
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-16       Impact factor: 4.052

2.  Effect of proton pump inhibitors on glycemic control in patients with diabetes.

Authors:  Kohzo Takebayashi; Toshihiko Inukai
Journal:  World J Diabetes       Date:  2015-08-25

3.  No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study.

Authors:  Olga Kruszelnicka; Marcin Kuźma; Iwona Z Pena; Ian B Perera; Bernadeta Chyrchel; Ewa Wieczorek-Surdacka; Andrzej Surdacki
Journal:  Int J Med Sci       Date:  2017-09-02       Impact factor: 3.738

4.  CCK-1 and CCK-2 receptor agonism do not stimulate GLP-1 and neurotensin secretion in the isolated perfused rat small intestine or GLP-1 and PYY secretion in the rat colon.

Authors:  Ida M Modvig; Charlotte B Christiansen; Jens F Rehfeld; Jens J Holst; Simon Veedfald
Journal:  Physiol Rep       Date:  2020-01

5.  Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists.

Authors:  Megumi Shiomi; Tesshu Takada; Yoichi Tanaka; Keiko Yajima; Akira Isomoto; Masaki Sakamoto; Katsuya Otori
Journal:  J Diabetes Investig       Date:  2018-08-22       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.